UNSPSC 51241127: Verteporfin

This classification denotes a porphyrin and photosensitizing agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0X9PA28K43. European Medicines Agency schedules Verteporfin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00044MIG. Verteporfin generally arises in the molecular formula C41H42N4O8. The term VERTEPORFIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, no. 3, 2004, list 52.) Most nations schedule Verteporfin under HS 29339990 and SITC 51577.

SMILES:. As of Q4 2014, VERTEPORFIN remains the US FDA Preferred Term for this commodity.. Verteporfin bears US NLM identifiers UMLS ID C0387288 and NCI Concept Code C1014.

UNSPSC 51241127 Verteporfin is a Commodity code representing branded and generic pharmaceutical products procured by state and local health systems, departments, and cooperative purchasing alliances. State and local governments buy verteporfin and related injectable pharmaceuticals through multi-source contracts administered by purchasing consortia, typically as part of broader generic and branded drug procurement frameworks that include negotiated pricing, wholesaler distribution agreements, and compliance with federal manufacturing and supply-chain standards.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), demonstrate current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, and maintain contractual relationships with at least two of the three wholesalers with chargeback systems in place. Evaluation is weighted heavily toward price competitiveness (75 percent), with the remainder allocated to fixed pricing structure (10 percent), administrative fee format compliance (5 percent), electronic data interchange capability (5 percent), and willingness to accept a 3 percent administrative fee (5 percent). Awards are effective July 1, 2026, with contract terms of two years for new vendors and alignment to existing agreements through June 30, 2028 for incumbents; MMCAP reserves discretion to make sole, dual, or multi-awards based on therapeutic need and member-specific requirements.